Released Mar 11, 2021, after the close
10-K filed Mar 11, 2021, 70 days after period end · 0001564590-21-012514
Q4 2020 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$0.00$0.00 derived−100.0% vs Q4 2019−100.0% vs Q3 2020
Net Income-$18.60M-$18.60M derivedN/M vs Q4 2019N/M vs Q3 2020
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$18,796,000N/M
Operating Cash Flowderived-$16,383,000N/M
Free Cash Flowderived-$16,395,000N/M
What the release said
The release
Same quarter
| Metric | Q4 2020dderived from reported figures | Q4 2019 | Q4 2018 | Q4 2017 |
|---|---|---|---|---|
| Revenue | $0.00 | $696.00K | $1.69M | $993.00K |
| Net Income | -$18.60M | -$24.99M | -$10.60M | -$13.86M |
| EPS Diluted | — | -$1.31 | -$0.60 | -$1.59 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR